Back

Encoded Therapeutics raises $275 million to advance Dravet gene therapy

Verifying
  • Encoded Therapeutics raised $275 million in a Series F financing to advance ETX101.
  • The round was co-led by GV and an undisclosed healthcare fund.
  • Encoded plans a pivotal trial and a 2027 Investigational New Drug submission for ETX301.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.